Clinical Utilization of Anti-VEGF Agents and Disease Monitoring in Neovascular Age-Related Macular Degeneration
- 1 April 2014
- journal article
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 157 (4), 825-833.e1
- https://doi.org/10.1016/j.ajo.2013.12.018
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Preferred therapies for neovascular age-related macular degenerationCurrent Opinion in Opthalmology, 2012
- Evaluation of Changes in Choroidal Neovascularization Secondary to Age-related Macular Degeneration after Anti-VEGF Therapy Using Spectral Domain Optical Coherence TomographyCurrent Eye Research, 2012
- Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked studyBMJ, 2010
- Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluationHealth Technology Assessment, 2008
- Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degenerationPublished by Wiley ,2008
- Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic reviewBritish Journal of Ophthalmology, 2007
- Causes and Prevalence of Visual Impairment Among Adults in the UnitedStatesAmerican Journal of Ophthalmology, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Causes of Blindness and Visual Impairment in a Population of Older AmericansThe Salisbury Eye Evaluation StudyAmerican Journal of Ophthalmology, 2000
- Increased expression of angiogenic growth factors in age-related maculopathyBritish Journal of Ophthalmology, 1997